The effect of dietary approaches to stop hypertension (DASH) diet on obesity

Comparison of the effect of dietary approaches to stop hypertension (DASH) diet with regular hypocaloric diet on on anthropometric indices, expression of some micro RNAs and genes involved in metabolic, inflammatory and hormonal status in obese adults

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20180712040438N5

Enrollment

120

Registered

2020-07-12

Start date

2020-07-25

Completion date

Unknown

Last updated

2020-08-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity. Overweight and obesity

Interventions

Intervention 1: Control group: They will use a diet based on the Iranian food pyramid and routine training that is normally provided by hospital nutrition experts. Intervention 2: Intervention group:

Eligibility

Sex/Gender

All

Age

20 Years to 50 Years

Inclusion criteria

Inclusion criteria: Body mass index 35-25 kg /m 2 Age range from 20 to 50 years old

Exclusion criteria

Exclusion criteria: Patients with severe diseases Pregnancy Alcohol consumption

Design outcomes

Primary

Measure	Time frame
Anthropometric indices. Timepoint: Baseline and End-of-trial. Method of measurement: Digital scale.;Blood sugar. Timepoint: Baseline and End-of-trial. Method of measurement: Automatic clinical chemical analysis device.;Lipid profile including TG, HDL-C, and TC. Timepoint: Baseline and End-of-trial. Method of measurement: Automatic clinical chemical analysis device.;Insulin. Timepoint: Baseline and End-of-trial. Method of measurement: Insulin.	—

Measure

Time frame

Anthropometric indices. Timepoint: Baseline and End-of-trial. Method of measurement: Digital scale.;Blood sugar. Timepoint: Baseline and End-of-trial. Method of measurement: Automatic clinical chemical analysis device.;Lipid profile including TG, HDL-C, and TC. Timepoint: Baseline and End-of-trial. Method of measurement: Automatic clinical chemical analysis device.;Insulin. Timepoint: Baseline and End-of-trial. Method of measurement: Insulin.

—

Secondary

Measure	Time frame
Adipokines levels include spixin, leptin, and adiponectin. Timepoint: At the beginning of the study (before intervention) and three months after the beginning of the intervention. Method of measurement: ElISA.;Interleukin 6 and 10. Timepoint: At the beginning of the study (before intervention) and three months after the beginning of the intervention. Method of measurement: ElISA.;Hs-CRP. Timepoint: At the beginning of the study (before intervention) and three months after the beginning of the intervention. Method of measurement: ElISA.;Expression of micro RNA 122a, mir15, mir155a, mir 146, mir 193. Timepoint: At the beginning of the study (before intervention) and three months after the beginning of the intervention. Method of measurement: RT-PCR.;PPARg Expression. Timepoint: At the beginning of the study (before intervention) and three months after the beginning of the intervention. Method of measurement: RT-PCR.;FTO Expression. Timepoint: At the beginning of the study (before intervention) and three months after the beginning of the intervention. Method of measurement: RT-PCR.;Bile acid (BA) profiles. Timepoint: At the beginning of the study (before intervention) and three months after the beginning of the intervention. Method of measurement: Elisa.;LPS. Timepoint: At the beginning of the study (before intervention) and three months after the beginning of the intervention. Method of measurement: ElISA.;Trimethylamine N-oxide. Timepoint: At the beginning of the study (before intervention) and three months after the beginning of the intervention. Method of measurement: ElISA.	—

Measure

Time frame

Adipokines levels include spixin, leptin, and adiponectin. Timepoint: At the beginning of the study (before intervention) and three months after the beginning of the intervention. Method of measurement: ElISA.;Interleukin 6 and 10. Timepoint: At the beginning of the study (before intervention) and three months after the beginning of the intervention. Method of measurement: ElISA.;Hs-CRP. Timepoint: At the beginning of the study (before intervention) and three months after the beginning of the intervention. Method of measurement: ElISA.;Expression of micro RNA 122a, mir15, mir155a, mir 146, mir 193. Timepoint: At the beginning of the study (before intervention) and three months after the beginning of the intervention. Method of measurement: RT-PCR.;PPARg Expression. Timepoint: At the beginning of the study (before intervention) and three months after the beginning of the intervention. Method of measurement: RT-PCR.;FTO Expression. Timepoint: At the beginning of the study (before intervention) and three months after the beginning of the intervention. Method of measurement: RT-PCR.;Bile acid (BA) profiles. Timepoint: At the beginning of the study (before intervention) and three months after the beginning of the intervention. Method of measurement: Elisa.;LPS. Timepoint: At the beginning of the study (before intervention) and three months after the beginning of the intervention. Method of measurement: ElISA.;Trimethylamine N-oxide. Timepoint: At the beginning of the study (before intervention) and three months after the beginning of the intervention. Method of measurement: ElISA.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactJalal Moludi

Kermanshah University of Medical Sciences

moludij@tbzmed.ac.ir+98 41 3335 2148

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026